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Among glycan-binding proteins, galectins, β-galactoside-binding lectins, exhibit relevant
biological roles and are implicated in many diseases, such as cancer and inflammation.
Their involvement in crucial pathologies makes them interesting targets for drug
discovery. In this review, we gather the last approaches toward the specific design of
glycomimetics as potential drugs against galectins. Different approaches, either using
specific glycomimetic molecules decorated with key functional groups or employing
multivalent presentations of lactose and N-acetyl lactosamine analogs, have provided
promising results for binding and modulating different galectins. The review highlights
the results obtained with these approximations, from the employment of S-glycosyl
compounds to peptidomimetics and multivalent glycopolymers, mostly employed to
recognize and/or detect hGal-1 and hGal-3.
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INTRODUCTION
Galectins are a large family of glycan-binding proteins with preference for β-galactoside- (β-
Gal) containing structures. In mammals, 16 different members have been described, which can
be found both in the intra- and extracellular environments. On the basis of the supramolecular
organization of their carbohydrate-recognition domains (CRDs), they are classified (Figure 1) as
prototype galectins, when a single CRD spontaneously forms homodimers (human galectins-1, -2,
-5, -7, -10, -11, -13, -14, -15, -16), as tandem-repeat galectins, when two homologous CRDs are
connected by a short aminoacidic linker (human galectin-4, -6, -8, -9, -12), or as chimera-type
galectins (human galectin-3), when the CRD is connected to an N-terminal aminoacidic non-lectin
region (Leffler et al., 2002; Yang et al., 2008; Dings et al., 2018). The sequence identity between
galectins is moderately high, and the CRD’s structure of six (from S1 to S6) and five (from F1 to F5)
antiparallel beta strands is always conserved (Figures 1, 2). The β-Gal-binding site is located in the
S-face, centered on subsite C and extended away, occupying subsites A, B, D, and E, which display
variations between the galectin members (Figure 1).
The canonical binding site of galectins is shallow and solvent exposed, and the interaction with
β-galactosides occurs through several hydrogen bonds between the hydroxyl groups of the β-Gal
and specific histidine, arginine, and asparagine galectin residues and through the CH-π stacking
interaction between the non-polar face of the β-Gal moiety and a conserved tryptophan residue
(Figure 2). Even though these residues in the binding site are highly conserved, the divergence
in few neighboring sites may modulate the glycan-binding preferences among galectins (Johannes
et al., 2018).
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FIGURE 1 | Above: representation of the three group of galectins. On the bottom: representation of the CRD of hGal-1 in complex with N-acetyllactosamine (PDB ID:
1W6P) with subsites (A, B, C, D, and E) of the binding site and architecture of the beta strands (S1, S2, S3, S4, S5, S6, F1, F2, F3, F4, F5, F6) highlighted.
Galectins are involved in a wide range of biological activities,
such as homeostasis, apoptosis, and vascular embryogenesis
(Chan et al., 2018). Their involvement in pathological contexts
has been described for inflammation (Brinchmann et al., 2018),
host-pathogen interaction (Vasta, 2009), antibacterial autophagy
(Weng et al., 2018), and cancer (Liu and Rabinovich, 2005;
Girotti et al., 2020). In fact, many members of the family
are associated with the phenomena of carcinogenesis being
involved in processes such as apoptosis, adhesion, migration,
cell transformation, invasion, metastasis, immune escape, and
angiogenesis (Dings et al., 2018). The heterogeneous roles of
galectins in these physiological and pathophysiological processes
have motivated the rational design of fine-tuned inhibitors with
precise selectivity and specificity. The characterization at the
molecular level of the interaction of galectins with their natural
binders has provided the structural basis for the design of potent
antagonists (Ardá and Jiménez-Barbero, 2018; Valverde et al.,
2019a).
Notwithstanding carbohydrates are the natural ligands of
galectins, they are not the best antagonist candidates because
of their inherent properties that make them not good enough
as pharmacological agents. The main disadvantages are the low
metabolic stability and high hydrophilicity. Moreover, it is well-
known that the affinities that characterize single carbohydrate-
lectin interactions are usually rather weak, in the µM-mM range,
far from the nM scale required for a good drug candidate. This
evidence derives from many factors intrinsically connected to
the nature of carbohydrates, such as the absence of hydrophobic
groups that can interact with the protein surface, the hydrogen
bond-based interplay with the binding site that suffers from
the competition with the bulk water, and the large enthalpic
penalties for desolvation of the shallow binding site (Hevey,
2019).
Thus, in the last two decades, molecular scaffolds
differently derivatized have been employed as mimetics
capable of recognizing and blocking galectins, especially
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FIGURE 2 | On the top: sequence alignment of the galectins discussed in this review. The residues conserved among galectins are highlighted in bold; the blue ones
are those mainly involved in the interaction with lactose. On the bottom: galectin’s binding sites of complexes (A) hGal-1/lactose (PDB ID: 1GZW), (B) hGal-3/lactose
(PDB ID: 2NN8), and (C) hGal-8-Nterminal/lactose (PDB ID: 5T7S). Residues involved in the interaction are displayed as sticks; H bonds are displayed as yellow dots.
human galectins 1 and 3 (hGal-1 and hGal-3) (Tellez-
Sanz et al., 2013; Blanchard et al., 2014, 2016; Girard and
Magnani, 2018). These glycomimetics are molecules that mimic
carbohydrates structurally and functionally but display improved
pharmacological properties (Magnani and Ernst, 2009).
The majority of the molecules synthesized for this purpose are
based on sugar scaffolds, although some non-saccharide-based
inhibitors, as peptide-based mimetics, have also been reported.
The chemical modifications of those based on sugar scaffolds
mainly concern the replacement of the endocyclic oxygen
of the pyranose ring (carbasugars, iminosugars, thiosugars,
and phosphasugars) or the exocyclic oxygen (C-glycosyl, N-
glycosyl, S-glycosyl). Indeed, the substitution of the bridging
exocyclic oxygen by other atoms has been proved to be effective
in increasing the resistance of carbohydrates to hydrolysis
(Tamburrini et al., 2019).
The workflow for the development of new glycomimetics aims
at finely modulate affinity and stability, as well as selectivity.
Since, as discussed, the CRD of mammalian galectins is highly
conserved, with minor amino acid sequence variation between
members of the family, achieving selective glycomimetics is
somewhat difficult and challenging (Figure 2) (Compain, 2018;
Tamburrini et al., 2019).
In addition to the modifications of the endocyclic or exocyclic
oxygen of the sugar scaffold, which modulate mostly stability
and conformation, the introduction of new functional groups
as substituents enables reaching new binding pockets and
establishes additional contacts, in order to increase affinity
and selectivity. Moreover, the development of potent inhibitors
usually resorts to the employment of multivalent ligands, which
exploits lectin avidity, and allows reaching increased affinities.
We have arbitrarily divided the glycomimetics design in this
area into two categories: strategies that exploit the presentation
of a single strong inhibitor (monovalent carbohydrate-based
inhibitors) and those that use multimerized ligands (multivalent
carbohydrate-based inhibitors). Below, the most recent and
promising examples for both types of inhibitors are presented
and contextualized.
SINGLE PRESENTATION STRATEGIES
As canonical natural ligands of galectins, lactose or N-
acetyllactosamine have been the most-used scaffolds to build
synthetic glycomimetics, although monosaccharides and other
disaccharides have also been taken into consideration and have
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FIGURE 3 | Binding site of the hGal-3/LacNAc (PDB ID: IKJL) and hGal-3/TDG (PDB ID: 4JC1) complexes. Key residues for binding are reported as sticks.
led to the synthesis of mimetics with promising characteristics
(Dings et al., 2018). All the monovalent carbohydrate-based
inhibitors can be defined as modified Gal-containing mono- or
disaccharides decorated with diverse molecular fragments.
On the molecular basis, the interaction of galectins with
β-galactoside sugars, besides the stacking interaction with the
conserved Trp moiety, mainly involves hydroxyl O4 and O6
of galactose (Figure 2). Therefore, the other positions are free
to accept modifications that can enhance the effectiveness of
the mimetic.
In fact, lactosamine derivates with modifications at Gal-
C3 (4-phenoxyaryl, via ether or triazole linkages) and Glc-
N2 (attachment of an aromatic phthaloyl or benzoyl) have
been synthetized, and their affinities have been measured using
fluorescence polarization assays (Sörme et al., 2004). These
molecules reached dissociation constants in the low µM range
for hGal-3 and hGal-1 (Van Hattum et al., 2013). Especially,
compound 1 (KD 1.2µM) was far more selective toward
hGal-3 over hGal-1 (230-fold) (Figure 5). The larger aromatic
substitution at Glc-N2 is better accommodated in the binding
site of hGal-3. Nevertheless, analogous modifications on a
non-hydrolysable thio-digalactoside (TDG) scaffold led to the
synthesis of glycomimetics showing high affinity (Van Hattum
et al., 2013).
The TDG scaffold (Figure 3) has proved to be an effective
platform for designing glycomimetics. These molecules
reproduce the interactions of lactosides at subsites C and D
of galectins with the advantage of being hydrolytically stable
(Figures 3, 4).
In particular, TD139, a symmetric TDG substituted with
aromatic moieties at each C3 position, has proved to be
a very good antagonist of hGal-1 and hGal-3 (MacKinnon
et al., 2012; Figure 5). Furthermore, the compound includes
fluorinated substituents, which can have an enormous impact in
protein-ligand interactions. Besides decreasing hydrophobicity,
the presence of fluorine atoms provides multiple ways to
interact with protein moieties, such as multipolar interactions
FIGURE 4 | Multipolar interactions between the fluorine atoms (blue sphere) of
compound 13 and hGal-3. C-F···H-N interactions are represented with purple
dashes. C-F···H-Cα interactions with green dashes. The C-F···C=O interaction
with the backbone amides of Arg144 and Ile145 is represented with yellow
dashes. PDB ID: 6QLP. The interactions are represented with analog 13
instead of TD139 since it lacks C-F···H-N and C-F···H-Cα interactions.
with carbonyl groups, amides, or dipole-dipole interactions
(Figure 4).
TD139 is one of the few examples of galectin’s antagonist in
advanced clinical trials (Galecto Biotech). In particular, it has
been employed as a therapeutic agent against hGal-3 for the
treatment of Idiopathic Pulmonary Fibrosis. Since the molecule
is not well-absorbed orally and must be given parenterally, the
method of administration is inhalation of dry powder.
Hsieh et al. (2016) have taken advantage of this scaffold to
target and analyze the interaction with hGal-1, -3, and -7. In
order to distinguish the implication of each aromatic group
of TD139 in the binding, TAZTDG, a mimetic with only one
aromatic substitution, was studied (Figure 5). 15N-1H HSQC
NMR titrations, 19F relaxation NMR experiments, Isothermal
Titration Calorimetry (ITC), and X-ray have unearthed that for
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FIGURE 5 | X-ray structures of hGal-3/TDG (PDB ID: 4JC1), hGal-3/TAZTDG (PDB ID: 5H9R), hGal-3/TD139 (PDB ID: 5H9P), and hGal-7/TAZTDG (PDB ID: 5H9S)
complexes. Galectin’s subsites and the key residues for the interaction are highlighted.
hGal-1 and -7, the aromatic ring contributes more to the binding
at the subsite E, whereas for hGal-3, the fluorophenyl group
is mainly interacting with subsite B (Figure 5). This kind of
information can be employed for the rational design of new
inhibitors, since different substituents at C3 can determine the
selectivity for a single galectin (Hsieh et al., 2016).
Delaine et al. (2016) have presented the synthesis of
a battery of doubly C-3 substituted derivatives at C3
(compounds 2-7, Figure 6). The generated 4-aryl-1,2,3-triazolyl
thiodigalactoside-based derivatives were tested as antagonists
of galectin-1, -2, -3, -4 (N- and C-terminal domain), -7, -8
(N-terminal domain), domain), and 9 (N- and C-terminal
domain) (Delaine et al., 2016). The molecules displayed
affinities considerably larger than those measured for the
unsubstituted thiodigalactosides, especially against hGal-1 and
hGal-3. Regarding hGal-1, this lectin bound the phenyl-triazole
unsubstituted 2with higher affinity (4 nM) than that formimetics
displaying larger substitutions (3, 84µM). Furthermore, only
the mimetic substituted with 3- or 4-fluorophenyl moieties (4,
12 nM; 5, 27 nM, respectively) weremore akin than unsubstituted
2, strongly suggesting that the galectin subsites display rather
limited possibilities for substitution, as previously described
(Van Hattum et al., 2013). Nevertheless, the thienyl substituted
compound 6 provided a very good inhibition of hGal-1 (KD <
10 nM, 2,400-fold stronger than TDG). Moreover, its selectivity
for hGal-1 over hGal-3 (65 nM) was remarkable. Concerning
hGal-3, the selectivity profile was similar to that achieved for
hGal-1, with the exception of the 4-phenoxy-substituted phenyl
3 that displayed a KD for hGal-3 of 0.36µM, with a considerably
enhanced selectivity over hGal-1 (KD of 84µM). It is evident
that the right choice of the substituent on the triazole ring of this
type of compounds guide selectivity for either hGal-1 or hGal-3.
Regarding hGal-4, the aryltriazoles carrying no substituents or
holding small appendages at the aryl moiety (2, 4, 5, 6, 7) were the
best inhibitors, especially for the C-terminal domain (mid-nM
affinities), in line with the observations for hGal-1. In contrast,
the N-terminal domain recognized all the molecules of the study
with low-mediumµMaffinities, with some notable exceptions (4,
0.17µM). The best inhibitor for the C-terminal domain was the
fluorophenyl-derivative 5 (73 nM). However, this molecule is not
specific, since it also recognized hGal-1 and hGal-3 within the
same affinity range. hGal-7 and hGal-9 (both C- and N-terminal
domains) did not efficiently bind the larger compounds of the
library, while they showed sub- to low-µM affinities for those
carrying small substituents. In contrast with the data for hGal-
4, no binding preferences were detected when compared the C-
and N-terminal domains of hGal-9.
X-ray crystallography structures of hGal-3 complexed with
the three best antagonists (4, 5, and 6), together with mutation
analysis of the lectin, showed that the aryl-triazol moieties display
guanidine-arene interactions involving R144 and R186, as well
as additional fluorine-amide orthogonal multipolar interactions,
which are obviously absent in the binding with the natural
ligands. The inhibition action of 4 against hGal-3 was also
corroborated with in vitro and in vivo strategies. The results
showed that 4 has intracellular availability and activity blocking
the intracellular accumulation of the lectin around damaged
vesicles in breast carcinoma MCF-7 cells and also attenuates
lung fibrosis in a dose-dependent manner, using a murine model
(Delaine et al., 2016).
On the basis of this success, a systematic tuning of the
aryl substituents was performed: a series of fluorinated
C3 aryltriazolyl-substituted thiodigalactosides, including
symmetrical and asymmetrical compounds, were synthesized to
optimize the interaction with R144 of hGal-3 (compounds 8-13,
Figure 6). As a first step, the interaction of monogalactosides
carrying phenyl-triazole moieties with fluorine, chlorine,
or bromine atoms was first evaluated, and the three best
inhibitors in terms of both affinity and selectivity for
hGal-3 over hGal-1 were selected. They include the di- or
trifluorophenyltriazol thiogalactosides (8, 9, and 10), with
relative affinities of 8.8, 15, and 5.2µM, respectively. Then,
the corresponding symmetrical thiodigalactosides (11, 12, 13)
were prepared, which displayed improved affinity and selectivity
compared to 4 and 5, as well as higher affinities over the
thiogalactosides 8, 9, and 10. However, the selectivity was lower
(Peterson et al., 2018).
In contrast, asymmetrically substituted thiodigalactosides
showed improved binding affinities and selectivity. The design
of these new compounds was based on the good selectivity
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FIGURE 6 | Structure of mimetics 1 (Van Hattum et al., 2013), TAZTDG (Hsieh et al., 2016), TD139 (MacKinnon et al., 2012), 2–6 (Delaine et al., 2016), 8–13
(Peterson et al., 2018), 14 (Nilsson et al., 2013), 15 (Salameh et al., 2010), and 16–19 (Peterson et al., 2018).
described for the analogous symmetrical molecules 14 (Nilsson
et al., 2013) and 15 (Salameh et al., 2010) and they combined the
monofluoro- and the trifluorophenyl moieties present in 4 and 13
with the coumaryl and triazolyl groups in 14 and 15 (Figure 6).
This new set of compounds (16, 17, 18, and 19) improved
hGal-3 over hGal-1 selectivity maintaining the low nM affinity
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FIGURE 7 | Structure of mimetics 20 (Zetterberg et al., 2018), 21 (Santarsia et al., 2018), and 25–29 (Dahlqvist et al., 2019). Structure of TF antigen and histo-blood
group antigens H, B, and A of type II (22–24).
(Figure 6). In particular, 17 (7.5 nM) was 46-fold more affine
for hGal-3. Structural analysis and ITC measurements revealed
that increased fluorination of a phenyl triazole group favors
the interaction with R144. In conclusion, the combination of
C3-aryltriazolyl groups with O3-coumaryl in a thiodigalactoside
generates a first-class glycomimetic with affinity and selectivity
for hGal-3 without equals (Peterson et al., 2018).
Additional improvements based on the monogalactoside
scaffolds 8, 9, and 10 have also been achieved. Zetterberg
et al. (2018) used a different approach, derivatizing the Gal
moiety at position 1 with an unnatural substituent, thus
favoring non-natural lectin-ligand interactions. They include
orthogonal multipolar fluorine-amide, phenyl-arginine, sulfur-
π, and halogen bond interactions. All the resulting compounds
[series of α- and β-thio-D-galactopyranosides with 4-(3,4,5-
trifluorophenyl)-1H-triazole at C3] bind to hGal-3 with very
good affinities. In particular, the S-glycoside 20, substituted with
a 3,4-dichlorophenylthio moiety (Figure 7) presents a KD of
37 nM, and it is fairly selective, with 100-fold lower affinity for
most of the other galectins (1, 4N, 7, 8C, 8N, 9C, 9N) and 20- and
4-fold for hGal-2 and hGal-4 C-terms, respectively (Zetterberg
et al., 2018).
The cellular uptake of some of these mimetics (4 with KD
of 12 nM, 20 with KD of 37 nM, and 15 with KD of 99 nM)
and their hGal-3 inhibition ability have been evaluated in
intracellular and extracellular environments (Stegmayr et al.,
2019). The permeability assays with monolayers of Caco-2
cells determined that 20 had a significantly higher value of
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membrane permeability (with passive transport) than 4 and 15.
Despite the relatively similar affinities, their polar surface area
is different, being significantly lower for 20, in good correlation
with the observed results. The extent of non-polar surface
areas is relevant for the passive cell membrane permeability
and oral bioavailability. Additionally, the extracellular activity
was tested using an assay based on the use of a fluorescently-
labeled hGal-3 coupled to the cell surface of CHO cells
line, revealing that the inhibition potency correlated with the
previously measured relative affinities. The determination of
the intracellular inhibition was based on the induction of the
accumulation of hGal-3 around damaged intracellular vesicles,
followed by the subsequent administration of the inhibitors. The
results followed the trend of the permeability assay, with 20
showing IC50 values considerably lower than those for 4 and 15
(Stegmayr et al., 2019).
Another promising disaccharide mimetic has been presented
byMarcelo and co-workers. The authors focused on the interplay
between hGal-3 and the Thomsen-Friedenreich (TF) antigen to
develop a mimetic capable of binding hGal-3 and compete with
the natural antigen (Santarsia et al., 2018). The TF antigen (20),
also known as pancarcinoma-related antigen, is a disaccharide
(Galβ1→3GalNAc) that decorates glycoproteins located on
the cell-surface through O-Ser/Thr linkages (Figure 7). Under
healthy conditions, this fragment is not exposed since it is
covered by additional glycosylation, and therefore hidden. In
contrast, the epitope is exposed and overexpressed in the tumor
microenvironment, particularly in adenocarcinomas (Springer,
1997; Glinsky et al., 2001). Now, the TF antigen is accessible and,
among other interactors, extracellular hGal-3, also overexpressed
in various tumor lines, is capable of recognizing and binding to
it, so mediating the adhesion of tumor cells to the endothelium
leading to metastasis progression (Jeschke et al., 2006; Fortuna-
Costa et al., 2014; Mori et al., 2015). MUC1 is a tumor-
related glycoprotein decorated with the TF antigen, and it has
been proposed that the aberrant interaction between MUC1
presenting TF disaccharide epitopes, and hGal-3 promotes cancer
progression (Glinsky et al., 2001; Goletz et al., 2002; Takenaka
et al., 2002). The authors exploited a previously proposed α-
O-Gal scaffold (Jiménez-Barbero et al., 2009) to generate the
disaccharide TF mimetic (21, Figure 7). 15N-1H HSQC-based
titrations provided the chemical shift perturbations of the hGal-3
signals, which revealed that the more affected protein residues
belong to the canonical binding site already described for the
natural TF antigen, both by NMR and X-ray crystallography
(Bian et al., 2011; Yongye et al., 2012). Linewidth 1H NMR and
STD-NMR experiments allowed to obtain the ligand-binding
epitope (Valverde et al., 2019b; Gimeno et al., 2020). Both
experimental procedures pointed out that the disaccharidic
moiety is the key epitope for hGal-3, while the unnatural scaffold
is exposed to the solvent. Similar observations have been reported
for the natural ligand TF, where the attached Thr does not
participate in the binding event (Santarsia et al., 2018). The
thermodynamic profile of the system indicate that there is a
slight gain in terms of KD, which interestingly arises from a
favorable entropic contribution (−0.9 kcal mol−1), while there
is less enthalpy gain (−4.3 kcal mol−1) compared to the natural
TF (–T1S 7.75 kcal mol−1; 1H −12.6 kcal mol−1) (Yongye
et al., 2012). The analysis of the X-ray crystallographic structure
obtained for the hGal-3/21 complex allowed noticing the absence
of four hydrogen bonds involving the GalNAc residue that were
present in the complex with the TF antigen, due to the chemical
nature of the lactam ring and the removal of the NHAc group.
These evidences might explain the loss of enthalpy gain; however,
they did not provide a completely definite explanation for the
observed positive entropic term. The authors suggested that
the amphiphilic character of the lactam ring and the associated
changes in the solvation features could be beyond the favorable
entropic contribution. This work is an exquisite example of
how a simple modification of the chemical nature of the ligand
can lead to a big change in the entropy-enthalpy compensation
phenomenon without changing the binding epitope. Overall,
mimetic 21 might be considered as a putative lead compound
to interfere with the aberrant interaction of hGal-3 and the TF
antigen (Santarsia et al., 2018).
In this context, and concerning the role of the entropy, a
multidisciplinary study of the interaction between the histo-
blood group antigens (Figure 7, hBGAs type II 22, 23, 24) and
hGal-3, revealed that the typical entropy penalty that occurs upon
galectin binding may be modulated by chemical modifications at
the ligand. For the hBGA tetrasaccharides, which are fucosylated
molecules, it was demonstrated that the fucose moiety rigidifies
the motion around the glycosidic linkages of the whole molecule,
thus providing a rather stiff and preorganized conformation. This
feature is reflected in the existence of faster association rates of
these ligands to hGal-3, which also exhibit a less unfavorable
binding entropy. Even if the fucose is not directly involved in
the binding event, it is capable of guiding the interaction and
improving the binding affinity. This evidence may be considered
to explore novel avenues for the development of more potent
ligands (Gimeno et al., 2019).
Simple C-glycosyl compounds have also been employed as
scaffolds for developing selective small-molecule inhibitors,
mainly involving C1- and C3-substitutions at the Gal
moiety. Nilsson and collaborators have proposed novel C1-
galactopyranosyl heterocycle mimetics that were fine-tuned
against galectins (Dahlqvist et al., 2019). Different triazoles,
oxazoles, isoxazoles, and pyrazoles (25–29, Figure 7) were used
as substituents at Gal C1 to generate a library that was tested
with galectins 1, 3, 4, 7, 8 (C- and N-terminal), and 9 (C- and N-
terminal). Competitive fluorescence polarization assays (Sörme
et al., 2004) allowed discriminating the more active compounds.
The triazole-substituted 25 and 26 mimetics were fairly selective
for hGal-1 (KD 750µM and 290µM, respectively) while the
oxazole-substituted 27 and 28 were selective for hGal-3 (KD
90µM and 230µM, respectively). These compounds presented
affinities only in the millimolar range with all the other galectins.
On the other hand, the isoxazoles displayed good affinity but
poor selectivity, while the pyrazoles were poorly active and
selective. Consequently, further design was accomplished using
the triazoles and the oxazoles as leads. Better affinity for hGal-1
was found for triazole 29 (KD 170µM), where the aryl moiety is
fluorinated at position 2, keeping the specificity for this galectin.
Molecular Dynamics (MD) simulations performed for the
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FIGURE 8 | Amino acidic sequence of different mimetics: anginex (Mayo
et al., 2001; Griffioen, 2006), 6DB7F (Mayo et al., 2003, 2008), DB16, and
DB21. β-sheets structures are reported as arrows.
hGal-1/29 complex revealed a stacking interaction between the
triazole ring of 29 and the His52 side chain of hGal-1. This His52
is unique for hGal-1 and differentiates it from the other galectins.
The specificity of 27 for hGal-3 was accounted for by the
occupation of the ligand of a unique subsite of the lectin above
the β-face of the bound Gal ring. The aforementioned workflow
can be followed to develop more high-affinity inhibitors by
exploiting the reported heteroaryl-selectivity (Dahlqvist et al.,
2019).
Besides sugar-based mimetics, non-carbohydrate inhibitors
have also been studied. In particular, carbohydrate-mimetic
peptides have been developed as effective inhibitors, taking
advantage of the role that peptides may play as immunogens
and interfere with protein–sugar interactions (Kieber-Emmons
et al., 2014). Using high-throughput phage display analysis,
a variety of synthetic peptides capable of binding to the
CRD of hGal-3 with high affinity, were identified as well
as their inhibition ability to affect metastasis-associated
cancer cell adhesion (Zou et al., 2005). The most active
peptides shared the common motif [P-(C)-G-P-X-X-X-
D-(C)-P]. Notably, G3-C12 (ANTPCGPYTHDCPVKR)
recognized hGal-3 with a KD of 70 nM, and its administration
significantly reduced metastatic cell deposition in a mice
model, consequently decreasing the outgrowth within
vasculature (Newton-Northup et al., 2013). Using N-
(2-hydroxypropyl)methacrylamide (HPMA) as a carrier
molecule, the drug delivery process was further enhanced
(Yang et al., 2014).
Anginex is an amphipathic synthetic peptide directed
against hGal-1, designed through basic folding principles, which
incorporates short sequences of interleukin-8, platelet factor-4
and the bactericidal/permeability increasing protein (Figure 8),
(Mayo et al., 2001; Griffioen, 2006). It is able to act as tumor
growth inhibitor and to block angiogenesis and migration of
cancer cells (Griffioen et al., 2001; Wang et al., 2012). It
adopts a major β-sheet topology, as deduced by NMR and
FIGURE 9 | Representation of compound PTX008 (Dings et al., 2006; Mayo,
2014).
CD experiments, and displays a net positive charge as well as
a hydrophobic face that are essential for its function (Dings
et al., 2003; Mayo et al., 2003). Concerning the specificity,
anginex preferentially targets hGal-1, although it is also capable
of binding to hGal-2, -7, -8N, and -9N with low affinities. In
contrast, it does not show any activity against hGal-3, -4N,
-4C, and 9-C 9-C (Salomonsson et al., 2011). Starting from
anginex’s sequence, other antagonist peptides of hGal-1 with
improved properties have been developed. Mayo et al. (2003,
2008) synthetized 6DBF7, in which keeping the β-sheet structure
presents a central dibenzofuran (DBF) scaffold that connects six
amino acid residues (at the N-term) to other seven amino acids
(at the C-term) (Figure 8). 6DBF7, which also targets hGal-1,
is more effective in vivo in terms of anti-angiogenic and anti-
cancer activity than parent anginex (Mayo et al., 2003, 2008). A
soluble analog, DB16, was employed to deduce the binding site
by 15N-1H HSQC NMR experiments. The interaction primarily
takes place at one edge of the β-sandwich of the lectin and
reduces the affinity of hGal-1 to lactose, suggesting the presence
of an allosteric interplay (Dings et al., 2013). The DB21 analog,
which shows a branched alkyl side chain (Figure 8) shows even
higher capacity to inhibit tumor angiogenesis and tumor growth
in vivo.
A series of non-peptidic topomimetics of anginex based
on a calix[4]arene scaffold substituted with hydrophobic and
hydrophilic moieties have also been employed (Dings et al.,
2006). Compound PTX008 (also known as OTX008) (Figure 9)
interacts with the lectin at an allosteric site (Dings et al.,
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FIGURE 10 | The multimeric lactosides employed by Gouin et al. (2010).
2008) and shows potent anti-angiogenic and anti-proliferation
activity in vitro and in vivo. In fact, it was approved for
Phase I clinical trials for advanced solid tumors (NCT number:
NCT01724320) (Thijssen et al., 2006; Mayo, 2014; Koonce et al.,
2017).
A series of peptides and phosphopeptides able to interact
with the hGal-3 CRD were also identified using fragments
from the N-terminal tail of hGal-3. HSQC experiments
using 15N-labeled hGal-3 CRD demonstrated the effective
interaction of the peptides with the back-face of the CRD
of hGal-3, also showing that phosphorylation of serines
6 and 12 enhances the binding, while phosphorylation of
tyrosines 107 and 118 in specific N-peptides attenuates the
interaction. These data also suggested a fine modulation
of hGal-3 activity through the phosphorylation of the tail
(Berbís et al., 2014).
MULTIVALENT PRESENTATION
STRATEGIES
In biological systems, low-affinity binding is usually overcome
through the engagement of simultaneous interactions that
the receptor and ligand can establish a phenomenon known
as multivalency (Chittasupho, 2012). Thus, mimicking nature
and developing multivalent ligands has been a frequent
approach to surmount the low affinity of single galectin-
carbohydrate interactions.
There are diverse ways in which multivalent presentations can
enhance affinity: chelation, subsite binding, statistical rebinding,
steric stabilization, and clustering effects (Cecioni et al., 2015;
Zhang et al., 2018; Bücher et al., 2019). However, in the
development of multivalent ligands, there are various factors
that should be taken into consideration. First, the nature of
the scaffold. Rigidity is a crucial feature to consider, since it
is directly related to entropy. Flexible linkers may display a
large entropic penalty upon binding. Second, flexibility can also
be advantageous because the linker might adopt the proper
conformation for favorable interactions to take place (Shewmake
et al., 2008; Hevey, 2019). Third, the chemical nature of the linker
is also relevant, since it might establish additional interactions
with secondary binding sites and therefore improve the affinity
(Boden et al., 2019). Undoubtedly, the choice of the ligand is
a key factor in the outcome as well as its actual concentration
within the scaffold. Usually, the higher the concentration of the
ligand is, the higher the affinity. However, at a high concentration
of the ligand, steric clashes may take place and the effectivity of
the approach decreases. Thus, the content of the specific ligand
should be carefully chosen (Karaman, 2010).
Despite that most of the described antagonists targeting
galectins are monovalent compounds, diverse multivalent
glycomimetics have been developed over the last decade. One
of the first designs of multivalent ligands targeting galectins was
proposed by Gouin et al. (2010). Multivalent ligands with a
glucose-based backbone and a lactose epitope targeting hGal-
1 and hGal-3 were designed (Gouin et al., 2010; Figure 10). In
order to address the relevance of valence, different multimeric
compounds were synthesized, varying the number of glucose
units and therefore the number of lactose moieties available in
the construct. The pendant chains also present ethylene glycol
spacers with different lengths, which affect the 3D structure and
flexibility of the cluster. Moreover, they were attached to the β-
1,4-linked glucose backbone using positions 1 or 6, thus, leading
to a variety of compounds that enabled the independent analysis
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of the effect of epitope-units and the spacer length (Rostovtsev
et al., 2002; Figure 13). This strategy has previously been applied
for the synthesis and binding studies of multivalent mannosides
with ConA (Gouin et al., 2007).
Competitive fluorescence polarization assays demonstrated
that the spacer length of the multimeric lactosides has no
relevant effect, since negligible differences in affinity toward
hGal-1 and hGal-3 were observed (Rostovtsev et al., 2002).
In fact, MD calculations suggested that the lactoside moieties
display a random localization, and the spacer length does not
alter the availability of the binding epitope. Two-site ELLA
experiments were employed to test the crosslinking ability of
the multilactosides, first with peanut agglutinin. In this case, the
relative potency per lactoside ranged from 2.1 to 3.2 (McCoy
et al., 1984). However, the crosslinking ability was not reproduced
for galectins, for which the affinity increased in proportion to
the lactose content. The best glycomimetic was the trivalent
compound, which yielded a KD of 16µM toward hGal-3, a <5-
fold affinity increase in comparison with the monovalent ligand.
A different glucose-based scaffold to bear disaccharide
epitopes has been proposed by Rahkila et al. (2019), consisting
of a dextran skeleton decorated with LacNAc moieties.
The idea behind this architecture was to mimic natural
polysaccharides (Rahkila et al., 2018). In particular, the
multivalent antagonists used a ca. 70 kDa dextran, which was
propargylated and bioconjugated with lactose, as well as with
mannobiose and maltose disaccharides (Grischenko et al., 2013)
as blank molecules. Interestingly, upon disaccharide coupling
through CuAAC, fractionation of the dextran occurred, yielding
multivalent ligands of ca. 40–50 kDa. Binding studies of the
multivalent conjugates were performed through 15N-1H HSQC
NMR titrations with the carbohydrate recognition domain of
hGal-3 and dextrans decorated with different lactose contents
were evaluated. Surprisingly, dissociation constants ranging
from 0.25 to 0.45mM were recorded, very similar to those
reported for free lactose (Diehl et al., 2010; Miller et al., 2016)
The lack of affinity enhancement suggests that the multiple
interactions do not cooperatively provide additional value to the
interaction, which might arise from unfavorable entropic costs
(Bernardi et al., 2014). Strikingly, although the titration with the
mannobiose multivalent ligand produced small chemical-shift
perturbations, a considerable decrease in the signal intensities
was observed in ca. 15 peaks, not located at the canonical
binding site of the lectin. Interestingly, these residues are located
in the opposite face of the binding site of the lectin and
belong to the region that was previously reported to interact
with β-mannans (Miller et al., 2016). Although the obtained
affinities did not provide positive multivalence effects, probably
due to the entropic costs caused by the flexible linker, and the
dextran backbone constitutes an easy to modify, well-defined,
and homogeneous scaffold to mimic natural-like polysaccharides
with possible applications as biomaterials.
Alternatively, Böcker et al. (2015) have employed neo-
glycoproteins based on bovine serum albumin (BSA) to target
human hGal-3. BSA is a highly abundant protein rich in lysine
residues, which makes it fairly appropriate for bioconjugation
(Blackmore and Eisoldt, 1999; Huang et al., 2004; Luyai
et al., 2009). Two different tetratrasaccharides (30, 31) were
synthesized in a chemo-enzymatically manner and coupled to
squaric acid diethyl ester to provide 32 and 33, which were
conjugated to BSA to provide two neo-glycoproteins series (34,
35) with specific glycans attached at different (between 0 and 29)
lysine residues (Figure 11).
The selective binding of the multivalent compounds to hGal-
1 and hGal-3 was tested through ELISA-type assays (Kupper
et al., 2013). The BSA conjugated with the LacNAc-LacNAcmotif
(34) displayed preference for hGal-3, as a result of the capability
of this lectin of recognizing the internal LacNAc motif, which
is rather weak for hGal-1 (Stowell et al., 2004). Interestingly,
the selectivity for hGal-3 decreased when the carbohydrate
content increases, even if the affinity was better. For BSA
conjugated with the LacDiNAc-LacNAc tetrasaccharide (35),
the affinity also increased with a higher carbohydrate content.
However, the selectivity between the lectins decreased. The
selectivity of ligands 35 toward hGal-3 was always higher, given
the low capability of hGal-1 to recognize LacDiNAc moieties
(Van den Berg et al., 2004; Rapoport et al., 2008). Therefore,
the interaction relies on the weak recognition of the internal
LacNAc. The affinity increase per glycan unit was then analyzed
at different lectin concentrations. The LacNAc-LacNAc series
34 did not show significant affinity enhancement. In contrast,
the LacDiNAc analogs 35, with 14 to 27 glycosylated lysines,
displayed multivalent effects with a 100-fold increase in the
relative potency per glycan. Overall, the best neo-glycoproteins
showed very high affinity (in the nM range) and selectivity
toward hGal-3.
As previously described, the addition of hydrophobic
residues to the Gal moieties at proper positions enhances
the affinity toward galectins. However, the corresponding
synthetic approach may involve laborious chemical procedures
(Sörme et al., 2003). In order to overcome this issue, Böcker
and Elling (2017) biotinylated the glycan epitopes attached
to BSA at position 6 of the non-reducing end through
enzymatic synthesis (Böcker and Elling, 2017). Fittingly,
the presence of biotin increased the affinity of the ligands
toward hGal-1 and hGal-3, maintaining the selectivity for
hGal-3. In fact, comparing biotinylated and non-biotinylated
neo-glycoproteins, the latter required higher glycosylation
densities to reach similar multivalent effects. In the presence
of biotin, six glycosylations were enough to obtain a KD
of 100 nM, whereas, in the absence of biotinylation, only
the analog with 14 glycosylations displayed a similar
binding affinity.
The LacDiNAc epitope has been widely employed for
decorating scaffolds in the seeking of selectivity. Bojarová
et al. (2018) have selectively targeted hGal-3 by employing
a series of HPMA [N-2(2-hydroxypropyl)methacrylamide]-
based nanocarriers (Figure 12) bearing this disaccharide motif
(Bojarová et al., 2018). HPMA, a biocompatible nanocarrier,
soluble in water and non-toxic (Ulbrich and Šubr, 2010), was
conveniently functionalized with alkyne and easily conjugated
to the desired sugar epitope. The neighborhood and content
of the alkyne-bearing groups was varied to provide multimeric
ligands with different carbohydrate contents (3 to 29 mol-%),
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FIGURE 11 | General scheme of the synthesis of the neo-glycoproteins. For neo-glycoproteins series 35 and 36 the surface of BSA is depicted in red, except for
lysine residues (blue), the attached carbohydrates are drawn with their symbolic representation. For each series of neo-glycoprotein, the number of lysines
glycosylated ranged from 0 to 29.
FIGURE 12 | Different scaffolds (A–D) used for targeting hGal-3. R = LacDiNAc. For each scaffold, polymers with different carbohydrate content were synthesized.
providing a platform to evaluate structure-activity relationships
(Figure 12). Additionally, the effect of the presence of a short
linker between the disaccharide and the triazole moieties was
also investigated.
Competitive inhibition ELISA-based assays of hGal-3 binding
to asialofetuin determined that a sugar content between 8 and
12 mol-% was optimal for providing the best relative potency
(rp/n) compared to the single LacDiNAc disaccharide. Direct
attachment of the sugar to the triazole moiety resulted in
an improvement in affinity compared with the more flexible
O-linked 2-ethylazido linker. Additional contacts between the
electron-rich ring with Arg186 at subsite E of hGal-3 are probably
at the origin of this effect. The presence of a phenyl group
attached to the triazole moiety (scaffold C) did not improve
the affinity when compared to scaffold A, whereas the presence
of the large DBCO linker (scaffold B) was detrimental for
binding. Overall, the best results were obtained for scaffold A,
with the LacDiNAc disaccharide (8.1 mol-% content) directly
attached to the triazole moiety, although a small rp/n value of 2.3
was achieved.
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FIGURE 13 | Glycopolymers designed for targeting hGal-1 and hGal-3. For each scaffold, five polymers were synthesized with different carbohydrate contents.
FIGURE 14 | The lactose-ferrocene conjugates targeting hGal-3.
A series of HPMA-based glycopolymers (Figure 13) bearing
different LacNAc contents (3.8 to 22.0 in mol-%) have been
designed (Tavares et al., 2020) and tested through an ELISA-
type assay.
The selectivity of the designed multimeric compounds for
hGal-1 was remarkable. The ligands displayed IC50 values in the
µM range vs. hGal-3, whereas nM affinities were achieved for
hGal-1. The best results were obtained for the glycopolymers
carrying monovalent scaffolds, with 19.9 and 20.6 mol-% of
glycan content, which displayed IC50 values in the low nM scale,
and for which each LacNAc unit was 166 times more potent than
that in the single presentation and 283 times more selective for
hGal-1 than for hGal-3.
In the lectin detection side, Martos-Maldonado et al. (2020)
have developed a series of lactose-ferrocene conjugates to
improve the sensitivity and reproducibility of hGal-3 detection.
This design was based in initial works that employed ferrocene-
sugar dendrimers and improved the sensing ability toward a
given lectin by combining the multivalent presentation features
with the multielectron exchange capability due to the presence
of multiple ferrocene units (Martos-Maldonado et al., 2013a,b).
In particular, four different ligands were designed targeting hGal-
3, three dendrimers with different lactose content: 36 (4 lactose
units), 37 (8), and 38 (16) and a monovalent ligand attached to
gold nanoparticles, withmore than 1,500 ligands per nanoparticle
(Figure 14).
ITC data demonstrated that the affinity was higher for
the multivalent dendrimers and improved for that with
the highest valency values (38). Intriguingly, although
the gold nanoparticle analog 39 displayed smaller affinity
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toward hGal-3, its sensing capability was extraordinary,
obtaining a detection limit of 160 nM. Overall, the three
dendrimers displayed affinity values in the range of the
most potent inhibitors previously developed, whereas the
gold nanoparticle is a promising electrochemical probe
that may enable the detection of hGal-3 at biologically
relevant concentrations.
CONCLUSIONS
High affinity and selective antagonists have been designed,
especially for hGal-1 and hGal-3, including various ligands that
are in clinical trials, although none of them are in the market
yet. The success of the mimetics designed on the basis of
single presentation strategies relies on the fact that not only
the canonical binding site of galectins has been targeted, but
also interactions with neighboring regions have been exploited
through the wise decoration of the sugar scaffold with specifically
designed functional groups, using a canonical medicinal
chemistry approach based on the continuous improvement of
the binding enthalpy factor. The use of symmetric molecules,
such as the TD139 and its pseudo-symmetric relatives, have
demonstrated to be in the good pathway. Nevertheless, the
control of the entropy factor, with the concomitant enthalpy-
entropy compensation phenomenon, remains challenging and
the next frontier, not only for the single presentation strategies
but especially for the design of glycoconjugates with multiple
epitope presentations. Except the chimera-type hGal-3, the other
galectins are dimers whose sugar-binding sites are located at
opposite spatial directions. Therefore, there is no obvious strategy
for tackling both binding sites in a simultaneous manner. The
proposed scheme for the best molecule should keep enough
flexibility to reach the target binding sites and thus enhance
avidity, but without paying a high entropic penalty. Usually,
typical lactose or N-acetyllactosamine molecules have been used
to decorate the multivalent scaffold, what implies that single-
binding events are of moderate affinity. There is room for
improvement at this point, using specific functional groups
and probably also using strategies that minimize the entropy
loss at the nanocarrier and/or at the interaction site. The
approaches employed so far have proved to be satisfactory and
are good starting points for further efforts. New biological roles
for galectins are continuously being shown. Thus, the design,
synthesis, and applications of galectin binders and sensors will
continue being an active field of research for the years to come.
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